Advertisement
Advertisement
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
4.14
USDSponsored
-0.01
-0.24%
Aug 07, 15:59 UTC -4
Closed
After-Market
4.14
0.00
0.00%
OKUR Earnings Reports
Positive Surprise Ratio
OKUR beat 12 of 21 last estimates.
57%
Next Report
Date of Next Report
Aug 18, 2026
Estimate for Q2 26 (Revenue/ EPS)
$170.00K
/-$0.54
Implied change from Q1 26 (Revenue/ EPS)
--
/-51.35%
Implied change from Q2 25 (Revenue/ EPS)
--
/-52.21%
OnKure Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On May 05, 2026, OKUR reported earnings of -1.11 USD per share (EPS) for Q1 26, missing the estimate of -0.75 USD, resulting in a -46.55% surprise. Revenue reached --, compared to an expected 170.00 thousand, with a -100.00% difference. The market reacted with a -9.96% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.54 USD, with revenue projected to reach 170.00 thousand USD, implying an decrease of -51.35% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were OnKure Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, OnKure Therapeutics, Inc. Class A Common Stock reported EPS of -$1.11, missing estimates by -46.55%, and revenue of $0.00, -100% below expectations.
How did the market react to OnKure Therapeutics, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -9.96%, changed from $4.52 before the earnings release to $4.07 the day after.
When is OnKure Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 18, 2026.
What are the forecasts for OnKure Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 3
analysts, OnKure Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.54 and revenue of $170.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement